Dimension Therapeutics, which is developing novel, liver-directed gene therapies for rare genetic disorders, filed on Monday with the SEC to raise up to $115 million in an initial public offering.
Dimension Therapeutics licenses its AAV vector gene delivery technology from REGENXBIO (RGNX), which is on the IPO calendar to raise $100 million this week.
Help employers find you! Check out all the jobs and post your resume.
